Results 21 to 30 of about 3,116,614 (307)
Signal Transduction and Targeted Therapy, 2020 Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately,
Weiwei Tang, Fan Wu, Qian Wang
exaly +2 more sources
The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma [PDF]
Frontiers in Oncology, 2021 Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Sorafenib is approved by the U.S. Food and Drug Administration to be a first-line chemotherapy agent for patients with advanced HCC.
Xinyao Hu +10 more
doaj +2 more sources
Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma [PDF]
Human and Experimental Toxicology, 2023 Ferroptosis is potential to relieve drug resistance in hepatocellular carcinoma (HCC). Glutathione peroxidase 4 (GPX4) is a critical modulator of ferroptosis. This study discussed the mechanism of GPX4-inhibited ferroptosis in sorafenib resistance in HCC.
X. Li +4 more
openalex +2 more sources
Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance [PDF]
British Journal of Cancer, 2021 Abstract Background This study aimed to investigate the possible role of inhibiting chromobox protein homologue 4 (CBX4) to deregulate of cancer stem cells (CSCs) and to evaluate the contribution of these molecules to sorafenib resistance in advanced hepatocellular carcinoma (HCC). Methods
Wei Zhao +8 more
openalex +3 more sources
Frontiers in Cell and Developmental Biology, 2023 Patients with hepatocellular carcinoma (HCC) bear a heavy burden of disease and economic burden but have fewer treatment options. Sorafenib, a multi-kinase inhibitor, is the only approved drug that can be used to limit the progression of inoperable or ...
Kangnan Zhang +4 more
doaj +2 more sources
Autophagy Facilitates the Sorafenib Resistance of Hepatocellular Carcinoma Cells [PDF]
West Indian Medical Journal, 2014 Liver cancer is the second most frequent cause of cancer death in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) represents the major subtype in liver cancer and its five-year survival rate remains very poor.
B Liu, Yanwei Cao, Hao Jiang, Anwei Mao
openalex +3 more sources
Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma. [PDF]
J Hepatocell CarcinomaHepatocellular carcinoma (HCC) is the most prevalent malignant tumor, characterized by a poor prognosis. In recent decades, both the incidence and mortality rates of HCC have risen sharply. Sorafenib has emerged as the first conventional drug approved by
Liu R +6 more
europepmc +2 more sources
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
Signal Transduction and Targeted Therapy, 2020 Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we
Wei Zheng, Kirill Gorshkov, Qiming Sun
exaly +2 more sources
BMC Cancer, 2023 Background Due to the high drug resistance of hepatocellular carcinoma (HCC), sorafenib has limited efficacy in the treatment of advanced HCC. Cancer-associated fibroblasts (CAFs) play an important regulatory role in the induction of chemoresistance ...
Jiali Zhao +12 more
doaj +2 more sources
Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Letter [PDF]
Molecular Cancer Therapeutics, 2014 Mazard and colleagues present results providing evidence that sorafenib favors irinotecan intracellular accumulation and enhances irinotecan toxicity via inhibition of the drug-efflux pump ABCG2 ([1][1]).
Malcolm A. Smith
openalex +3 more sources